Contraception 2000: lunelle, an injectable combination contraceptive option

Area of Science:

• Reproductive Health
• Endocrinology
• Pharmacology

Background:

• Current contraceptive options include daily pills, patches, and long-acting injectables.
• Women seek convenient, effective, and well-tolerated reversible contraceptive methods.
• The need for diverse contraceptive choices to meet individual needs is recognized.

Purpose of the Study:

• To introduce and describe a novel once-a-month injectable contraceptive.
• To highlight the composition and expected benefits of MPA/E2C.
• To discuss the potential impact of this new contraceptive on women's reproductive health choices.

Main Methods:

• The abstract describes a new injectable contraceptive formulation.
• It details the active ingredients: medroxyprogesterone acetate and estradiol cypionate (MPA/E2C).
• It discusses the expected pharmacological and clinical profile based on its components.

Main Results:

• The injectable contraceptive MPA/E2C is anticipated to receive FDA approval.
• It combines the efficacy of long-acting methods with the cycle control of oral contraceptives.
• It is expected to have a favorable side effect profile and facilitate return to fertility.

Conclusions:

• The introduction of MPA/E2C will expand safe and effective contraceptive options for women in the US.
• This monthly injectable may appeal to women who have not used existing reversible methods consistently.
• It offers a new convenient choice for family planning and reproductive health management.